ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First-of-its-Kind trial aims to tame blood cancer with triple punch
Disease control OngoingThis early-stage study is testing a new combination of three drugs—rituximab, lenalidomide, and ibrutinib—in adults with previously untreated follicular lymphoma, a type of blood cancer. The main goal is to find the safest and most effective doses of the two newer drugs (lenalido…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New Three-Drug attack on tough lymphomas
Disease control OngoingThis study is testing a new three-drug combination to control B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see if adding a new immunotherapy drug (ALX148) to two existing drugs (rituximab and lenalidomide) helps patients whose cancer has returned or is newly d…
Matched conditions: ANN ARBOR STAGE III GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC